Last checked at 21 Dec 2017 07:05
21 DECEMBER 2017 |
ImmuPharma PLC
("ImmuPharma" or the "Company")
Grant of Options
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 900,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to certain of its consultants who have been directly involved in Lupuzor™'s successful development to date, representing 0.679% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis (the "Options"). The Options were granted upon the recommendation of the Company's remuneration committee.
The exercise price for the Options is 153 pence being the closing middle market share price on 20 December 2017. The Options will vest subject to certain conditions after three years and are exercisable between three and ten years from the date of grant.
Total Share Options
The total options outstanding under both the 2017 Plan and the Company's previous share option plan is 10,130,000, representing 7.64% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis. The total options outstanding that have been granted to non-employees and consultants is 6,085,000. The total warrants outstanding is 153,850. Taken altogether, there are currently 16,368,850 outstanding options and warrants, representing 12.35% of ImmuPharma's Ordinary Shares and total voting rights on a fully diluted basis.
This announcement contains inside information for the purpose of Article 7 of Regulation (EU) 596/2014.
Ends
For further information, please contact:
ImmuPharma plc (www.immupharma.co.uk) |
|
Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations Twitter: @immupharma
| +44 (0) 20 7152 4080 +44 (0) 7721 413496 |
Northland Capital Partners Limited (NOMAD & Broker) Patrick Claridge, Corporate Finance David Hignell, Corporate Finance Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking | +44 (0) 20 3861 6625 |